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Background: Despite advances in neonatal care, sepsis remains a threat, in particular for premature
neonates, due to immature immunologic defense. Deﬁcient chemotaxis, an essential process in the host
response to pathogens, may contribute to this vulnerability. In this study we investigated chemokine
expression in septic premature and term neonates.
Methods: Seventy-one neonates with signs and symptoms suggestive of systemic infection, requiring
full sepsis evaluation and treatment, formed the study group; 58 neonates without sepsis served as the
control group. Serum concentrations of twoa-chemokines (GRO-a and ENA-78) and two b-chemokines
(RANTES and MIP-1a) were measured at day 0 and day 3–5 of infection in the study group, and on the
day of inclusion in the study in the control group.
Results: During infection, serum levels of GRO-a in the study group were higher and serum levels of
RANTES were lower as compared to those of the control group (p < 0.001 and p < 0.001, respectively).
Furthermore, levels of GRO-a were higher and levels of RANTES were lower on day 0 as compared to
levels on day 3–5 (p < 0.001 and p < 0.001, respectively). Chemokine serum concentrations on day 3–5
in the study group did not differ signiﬁcantly as compared to those of the control group. Term and
preterm infants seemed to respond similarly regarding chemokine expression. No signiﬁcant differences
were found in serum levels of MIP-1a and ENA-78.
Conclusions: Our ﬁndings suggest up-regulation of GRO-a and down-regulation of RANTES at the onset
of a septic episode, similar to the response pattern observed in septic adults. Both term and preterm
neonates appear to have the potential to elicit a chemotactic response to infection.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Neonatal sepsis is a life-threateningevent affecting 3–5neonates
per 1000 live-births.1 Despite advances in neonatology, the threat of
infection has not been eliminated, especially in preterm infants,
leading to a substantial morbidity and mortality.2,3 Neonatal
susceptibility to infections is related to immature immunologic
defense.4 Recruitment of leukocytes to the site of pathogen invasion
is an essential part of host’s response to infection.5 Chemotactic
cytokines, collectively known as chemokines, appear to have the
capacity to control the movement of leukocytes and are crucial
elements in this process.5,6 a-Chemokines predominantly recruit
neutrophils and b-chemokines attract lymphocytes, monocytes,
eosinophils, basophils, and natural killer cells.6
Chemotaxis is deﬁcient in neonates, particularly those deliv-
ered prematurely, and this may contribute to their increased* Corresponding author.
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doi:10.1016/j.ijid.2010.03.015vulnerability to sepsis.7 However the role of chemokines in
neonatal infections has not been extensively investigated, with the
exception of interleukin-8 (IL-8).8 Few studies have reported the
neonatal chemokine response to infections.9–11 Some chemokines
(GRO-a, MCP-1, IP-10, andMIG) have been reported to be higher in
infected than healthy neonates, while RANTES has been reported
lower.9–11 High levels of MIP-1a have been documented in
adults.12 Other chemokines, including ENA-78, have not been
measured in infected neonates.
The aim of this study was to investigate the magnitude of the
serum concentration of two a-chemokines (GRO-a and ENA-78)
and twob-chemokines (RANTES andMIP-1a) in term and preterm
septic neonates.
Materials and methods
Study population
From January 2003 through December 2006, 129 neonates
admitted to the Department of Neonatology at Heraklionses. Published by Elsevier Ltd. All rights reserved.
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and preterm neonates with signs and symptoms suggestive of
systemic infection or necrotizing enterocolitis (NEC), requiring full
sepsis evaluation and antibiotic treatment, formed the study
group. Fifty-eight neonates admitted to our department for
miscellaneous reasons other than infection formed the control
group. Four subgroups were further formed in order to investigate
differences in chemokine response to infection between term and
pretermneonates: study group I (42 term infected neonates), study
group II (29 preterm infected neonates), control group I (38 non-
infected term neonates), and control group II (20 non-infected
premature neonates). Neonates with evidence of major congenital
malformations, inborn errors of metabolism, or chromosomal
anomalies were excluded from the study.
Deﬁnitions
Sepsis was deﬁned when blood and/or cerebrospinal ﬂuid
cultures were positive, along with supporting clinical ﬁndings. In
the case of a negative blood culture, sepsis was deﬁned in the
presence of laboratory ﬁndings suggestive of infection (positive C-
reactive protein, neutrophilia/neutropenia, thrombocytopenia,
elevated erythrocyte sedimentation rate) in combination with at
least three of the following groups of symptoms and signs: (1)
paleness or jaundice, (2) persistent tachypnea (>60 breaths/min),
retractions, respiratory distress, (3) lethargy, apnea, persistent
bradycardia (<100/min), seizures or irritability, (4) poor peripheral
circulation, persistent tachycardia (>160/min) or hypotension, (5)
distension of the abdomen or vomiting, and (6) fever or
hypothermia (<36.5 8C or >37.5 8C).13 Neonates born at less than
37 weeks of gestation were deﬁned as preterm.
Chemokine determination
Two blood samples were obtained from the study group: the
ﬁrst during sepsis evaluation, before initiation of antibiotic
treatment, and the second after three to ﬁve days of treatment.
For the control group, blood samples were obtained at the time of
inclusion in the study. The blood samples were immersed in ice
and transported to the laboratory for processing within 1 h. They
were centrifuged at 1000  g (g: 9.806 m/s2) for 10 min, and the
serum separated and stored at 20 8C until assay. Chemokine
concentrations were determined by use of commercially available
immunoassay kits (R&D Systems; human CCL3/MIP-1a, catalog
number DMA00; human CXCL1/GRO-a, catalog number DGR00;
human RANTES, catalog number DRN00B; human ENA-78, catalog
number DX000). All analyses were performed in residual blood
samples obtained during the routine investigation. The study was
approved by the Hospital Research Ethics Committee.
Statistical analysis
Descriptive statistics of chemokines are given as the mean and
median (range). Differences in values between study and control
groups were compared using the Mann–Whitney U-test. Compar-
isons of values between day 0 and day 3–5 were performed usingTable 1
Clinical features of the study neonates
Study, term Stu
No. of infants 42 29
Birth weight (g) 3135 ( 537) 130
Gestational age (weeks) 38.4 ( 1.1) 31.
Male/total ratio (%) 28/42 (67) 12/
Age at ﬁrst sample (days after birth) 10 ( 6.3) 11.
Values are expressed as mean and standard deviation.theWilcoxon signed ranks test. All statistical tests were performed
with SPSS for Windows (SPSS Inc., Chicago, IL, USA). The level of
signiﬁcance was set at 5% for all comparisons.
Results
A total of 129 neonates were enrolled in the study, 71 in the
study group and 58 in the control group. No signiﬁcant differences
in demographics and clinical characteristics were observed
between the full-term groups (study vs. control) and preterm
groups (study vs. control) (Table 1). At the time of the sepsis
episode, 10 premature neonates were on mechanical ventilation,
one had an intraventricular hemorrhage, and two had periven-
tricular leukomalacia, while in the preterm control group, two
babies were on mechanical ventilation, three had respiratory
distress syndrome, and two infants had periventricular leukoma-
lacia.
Serum levels of investigated chemokines on day 0 are shown in
Table 2. Levels of GRO-a in the study group at the time of sepsis
investigation were signiﬁcantly higher and levels of RANTES were
signiﬁcantly lower as compared to those of the control group.
Serum levels of all four chemokines studied on day 0 and day 3–
5 for the study group and serum levels on day 0 for the control
group are shown in Figure 1. Serum levels of GRO-a in infected
neonates were signiﬁcantly higher on day 0 as compared to levels
on day 3–5. The RANTES serum concentration in the study group
was signiﬁcantly lower on day 0 compared to the concentration on
day 3–5. No signiﬁcant differences in serum levels of MIP-1a and
ENA-78 were found between groups. Chemokine serum concen-
trations on day 3–5 in the study group did not differ signiﬁcantly as
compared to those of the control group.
Concentrations of GRO-a and RANTES levels in both subgroups
of term and preterm study neonates were signiﬁcantly different as
compared to their controls, while serum concentrations of ENA-78
and MIP-1a did not differ signiﬁcantly between subgroups
(Table 2). RANTES serum levels in premature infants were
signiﬁcantly lower, both on day 0 and day 3–5, in the study group
as compared to those of term neonates. GRO-a, ENA-78, and MIP-
1a did not differ signiﬁcantly between the two groups (Table 3).
Discussion
Our ﬁndings suggest that GRO-a and RANTES concentrations
are signiﬁcantly different in both term and pretermneonates at the
onset of a septic episode, as compared to those of non-infected
infants. GRO-a serum levels have been shown to be higher in
infected neonates, and similar ﬁndings have recently been
reported for septic preterm neonates,9 adults with sepsis,14 and
in cord blood serum of preterm newborns with early sepsis.15
RANTES serum levels were found to be signiﬁcantly lower at the
early stage of the septic process compared to those of non-infected
neonates. Recent studies in septic neonates have also shown a
similar decrease in this chemokine concentration in term and
preterm neonates.9–11 The same pattern of RANTES response to
sepsis has been reported in animal studies16,17 and in adults.18–20 It
is of interest that elevated levels of GRO-a declined signiﬁcantlydy, premature Control, term Control, premature
38 20
5 ( 483.2) 3245 ( 498.3) 1590 ( 366.2)
1 ( 3.4) 38.1 ( 1.1) 32.8 ( 2.2)
29 (41) 26/38 (68) 6/20 (30)
1 ( 10.3) 9.37 ( 7.6) 9.25 ( 7.18)
Table 2
Serum levels of GRO-a, RANTES, MIP-1a, and ENA-78 in term and preterm neonates with and without sepsis, on day 0. Chemokine serum levels in the groups of term and
preterm neonates, separately, are also presented. Results are mean; median (range)
Chemokine
(pg/ml) All neonates
p-Value Term neonates p-Value
Preterm neonates
p-Value
Study n=71 Control n=58 Study n=42 Control n=38 Study n=29 Control n=20
GRO-a 697; 434
(140–3580)
277; 277
(75.9–526)
<0.001 759; 421
(147–3580)
281; 277
(75.9–526)
<0.05 603; 559
(140–1460)
269; 279
(124–417)
<0.05
RANTES 27 870; 22 445
(225–96 160)
45 225; 39 490
(11 110–97 110)
<0.001 34 808; 34 100
(2422–96 160)
45 694; 38 680
(16 420–97 110)
<0.05 17 334; 11 650
(225–77 830)
44 334; 40 220
(11 110–87 790)
<0.001
MIP-1a 75.5; 40.7
(3.31–1144)
42.5; 43.4
(10.2–77.8)
0.947 93.8; 42.1
(3.31–1144)
42.7; 40.8
(10.20–77.8)
0.969 49.7; 37.8
(19.3–204)
42.2; 43.4
(20.4–70.1)
0.947
ENA-78 1871; 1436
(78.5–9300)
2081; 1754
(365–5393)
0.069 1874; 1578
(78.5–9300)
2213; 1970
(742–5393)
0.095 1867; 1196
(217–7790)
1817; 1486
(365–4843)
0.448
GRO-a, growth-related oncogene-a; RANTES: regulated upon activation of normal T cell expressed and secreted; MIP-1a, macrophage protein-1a; ENA-78, epithelial
neutrophil activating peptide-78.
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antibiotic treatment, and that this normalization was observed in
RANTES concentration with the decreased levels rising and
reaching control levels on day 3–5. Similar results have been
demonstrated in a recent study in preterm infants,9 although
persisting low levels of RANTES in perinatally infected neonates on[(Figure_1)TD$FIG]
Figure 1. Serum GRO-a, RANTES, MIP-1a, and ENA-78 concentrations in neonates w
hospitalization).day 4 after birth compared to controls have been shown
elsewhere.10 This discrepancy in results may be attributed to
the small proportion of perinatally infected neonates in our cohort
(16/71).
No difference was found in serum concentrations of MIP-1a
and ENA-78 between infected and non-infected infants. The veryith sepsis (day 0 and day 3–5 of hospitalization) and without sepsis (day 0 of
Table 3
Serum levels of GRO-a, RANTES, MIP-1a, and ENA-78 in term versus preterm neonates with sepsis at day 0 and term versus preterm neonates at day 3–5 of hospitalization.
Results are mean; median (range)
Chemokine
(pg/ml)
Day 0 p-Value Day 3–5 p-Value
Study term Study preterm Study term Study preterm
GRO-a 759; 421 (147–3580) 603; 559 (140–1460) 0.698 286; 277 (52–569) 221; 203 (63–1010) 0.052
RANTES 34 808; 34 100 (2422–96 160) 17 334; 1650 (225–77 830) <0.001 62 061; 57 155 (11 190–270 000) 31 879; 26 875 (3509–92 470) <0.001
MIP-1a 93.8; 42.1 (3.31–1144) 49.7; 37.8 (19.3–204) 0.831 34.7; 29.4 (5.20–70.1) 77.9; 32.7 (8.33–618) 0.631
ENA-78 1874; 1578 (78.5–9300) 1867; 1196 (217–7790) 0.638 2088; 1626 (215–7100) 1635; 1261 (250–6734) 0.222
GRO-a, growth-related oncogene-a; RANTES: regulated upon activation of normal T cell expressed and secreted; MIP-1a, macrophage protein-1a; ENA-78, epithelial
neutrophil activating peptide-78.
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controversial ﬁndings; MIP-1a has been reported higher in
neonates with perinatal infection as compared to controls, while
no difference was observed in those with nosocomial infection.10
ENA-78 in septic adults has been shown not to differ in
comparison to levels in healthy controls.14 To the best of our
knowledge, ENA-78 has not been previously measured in septic
neonates; our ﬁrst ﬁndings thus conﬁrm the ﬁndings of studies in
adults.
Our results suggest that the chemokine response to infection is
similar in term and preterm neonates. In two previous studies,
serum concentrations of chemokines (ENA-78, GRO-a, RANTES,
MIP-1a, eotaxin, IL-8) in non-infected preterm neonates were
similar to those measured in term infants.21,22 However, in our
study, the RANTES serum concentration in infected neonates was
found tobe signiﬁcantly lower inpretermthan in term infants, at the
onsetof the septic episodeaswell as 3–5days afterwards. This result
may reﬂect the difference in severity of infection and adverse
outcome between premature and term infected neonates in our
cohort; ﬁve of 29 infected premature neonates died, four of them
because of NEC, whereas only one of 42 infected term neonates had
an adverse outcome. Our result is in accordance with previous
studies in adults showing that circulating RANTES concentrations
were inversely correlated with the APACHE II score18 and adverse
outcome.18,20 A recent study inpreterm infants also showed that the
RANTES concentrationwas signiﬁcantly lower in infantswith severe
sepsis and disseminated intravascular coagulation compared with
less seriously infected infants.11
Although we tried to investigate four chemokines in the same
cohort, more research is really required towards understanding
the complex interplay of the numerous chemokines and
cytokines in the neonatal host’s response to infection. As the
majority of infected infants (55/71) had a late-onset infection in
our study, more research on early-onset infection is obviously
required.10
In summary, our ﬁndings suggest thatmembers of thea- andb-
chemokine families are involved in the neonatal host response to
sepsis, both in term and in preterm neonates. The patterns of up-
regulation of GRO-a and down-regulation of RANTES at the onset
of a septic episode were shown to be similar to those observed in
septic adults. Term as well as preterm neonates appear to have the
potential to elicit a chemotactic response to infection, however
future studies are needed to elucidate the exact role of chemokines
in neonatal sepsis.
Conﬂict of interest: No conﬂict of interest to declare.References
1. Kaushik SL, Parmar VR, Grover N, Grover PS, Kaushik R. Neonatal sepsis in
hospital born babies. J Commun Dis 1998;30:147–52.
2. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Late
onset sepsis in very low birth weight neonates: the experience of the NICHD
Neonatal Research Network. Pediatrics 2002;110:285–91.
3. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al.
Changes in pathogens causing early-onset sepsis in very-low-birth-weight
infants. N Engl J Med 2002;347:240–7.
4. Schultz C, Temming P, Bucsky P, Go¨pel W, Strunk T, Ha¨rtal C. Immature anti-
inﬂammatory response in neonates. Clin Exp Immunol 2004;135:130–6.
5. Luster AD. Chemokines—chemotactic cytokines that mediate inﬂammation. N
Engl J Med 1998;338:436–45.
6. Rollins BJ. Chemokines. Blood 1997;90:909–28.
7. Carr R. Neutrophil production and function in newborn infants. Br J Haematol
2000;110:18–28.
8. LamH, Ng P. Biochemical markers of neonatal sepsis. Pathology 2008;40:141–8.
9. Ng P, Li K, Chui K, Leung T, Wong R, Chu W, et al. IP-10 is an early diagnostic
marker for identiﬁcation of late-onset bacterial infection in preterm infants.
Pediatr Res 2007;61:93–8.
10. Fotopoulos S, Mouchtouri A, Xanthou G, Lipsou N, Petrakou E, Xanthou M.
Inﬂammatory chemokine expression in the peripheral blood of neonates with
perinatal asphyxia and perinatal or nosocomial infections. Acta Paediatr
2005;94:800–6.
11. Ng P, Li K, Leung T,Wong R, Li G, Chui K, et al. Early prediction of sepsis-induced
disseminated intravascular coagulation with interleukin-10, interleukin-6, and
RANTES in preterm infants. Clin Chem 2006;52:1181–9.
12. Knapp S, Thalhammer F, Locker GJ, Laczika K, Hollenstein U, Frass M, et al.
Prognostic value of MIP-1a, TGF-b2, sELAM-1, and sVCAM-1 in patients with
Gram-positive sepsis. Clin Immunopathol 1998;87:139–44.
13. Ng P, Cheng SH, Chui KM, Fok TF, Wong MY, Wong W, et al. Diagnosis of late
onset neonatal sepsis with cytokines, adhesion molecules, and C-reactive
protein in preterm very low birthweight infants. Arch Dis Child Fetal Neonatal
Ed 1997;77:F221–7.
14. Cummings CJ, Martin TR, Frevert CW, Quan JM, Wong VA, Mongovin SM, et al.
Expression and function of the chemokine receptors CXCR1 and CXCR2 in
sepsis. J Immunol 1999;162:2341–6.
15. Kro´lak-Olejnik B, Beck B, Olejnik I. Umbilical serum concentrations of chemo-
kines (RANTES and MGSA/GRO-a) in preterm and term neonates. Pediatr Int
2006;48:586–90.
16. Kopydlowski KM, Salkowski CA, Cody MJ, van Rooijen N, Major J, Hamilton TA,
Vogel SN. Regulation of macrophage chemokine expression by lipopolysaccha-
ride in vitro and in vivo. J Immunol 1999;168:3195–204.
17. Frangogiannis NG, Mendoza LH, Smith CW, Michael LH, Entman ML. Induction
of the synthesis of the C–X–C interferon-gamma-inducible protein-10 in ex-
perimental canine endotoxemia. Cell Tissue Res 2000;302:365–76.
18. Cavaillon JM, Adib-Conquy M, Fitting C, Adrie C, Payen D. Cytokine cascade in
sepsis. Scand J Infect Dis 2003;35:535–44.
19. Møller AS, Bjerre A, Brusletto B, Joø GB, Brandtzaeg P, Kierulf P. Chemokine
patterns in meningococcal disease. J Infect Dis 2005;191:768–75.
20. Appay V, Rowland-Jones SL. RANTES: a versatile and controversial chemokine.
Trends Immunol 2001;22:83–7.
21. Sullivan SE, Staba SL, Gersting JA, Hutson AD, Theriaque D, Christensen RD,
Calhoun DA. Circulating concentrations of chemokines in cord blood, neonates
and adults. Pediatr Res 2002;51:653–7.
22. Schultz C, Rott C, Temming P, Schlenke P, Moller JC, Bucsky P. Enhanced
interleukin-6 and interleukin-8 synthesis in term and preterm infants. Pediatr
Res 2002;51:317–22.
